- Home
- OVID vs TENX Comparison
OVID vs TENX Comparison
Compare OVID & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVID
- TENX
- Stock Information
- Founded
- OVID 2014
- TENX 1967
- Country
- OVID United States
- TENX United States
- Employees
- OVID N/A
- TENX N/A
- Industry
- OVID Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- OVID Health Care
- TENX Health Care
- Exchange
- OVID Nasdaq
- TENX Nasdaq
- Market Cap
- OVID 24.0M
- TENX 21.6M
- IPO Year
- OVID 2017
- TENX N/A
- Fundamental
- Price
- OVID $0.29
- TENX $5.57
- Analyst Decision
- OVID Strong Buy
- TENX Strong Buy
- Analyst Count
- OVID 6
- TENX 3
- Target Price
- OVID $3.03
- TENX $16.00
- AVG Volume (30 Days)
- OVID 376.8K
- TENX 12.8K
- Earning Date
- OVID 05-20-2025
- TENX 05-20-2025
- Dividend Yield
- OVID N/A
- TENX N/A
- EPS Growth
- OVID N/A
- TENX N/A
- EPS
- OVID N/A
- TENX N/A
- Revenue
- OVID $566,000.00
- TENX N/A
- Revenue This Year
- OVID N/A
- TENX N/A
- Revenue Next Year
- OVID $36.11
- TENX N/A
- P/E Ratio
- OVID N/A
- TENX N/A
- Revenue Growth
- OVID 44.39
- TENX N/A
- 52 Week Low
- OVID $0.24
- TENX $2.77
- 52 Week High
- OVID $3.43
- TENX $7.89
- Technical
- Relative Strength Index (RSI)
- OVID 39.90
- TENX 46.68
- Support Level
- OVID $0.28
- TENX $5.49
- Resistance Level
- OVID $0.33
- TENX $5.87
- Average True Range (ATR)
- OVID 0.03
- TENX 0.34
- MACD
- OVID 0.00
- TENX 0.03
- Stochastic Oscillator
- OVID 16.97
- TENX 68.71
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.